Citations (10)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (2)
Peter M. Haddad & Christoph U. Correll. (2023) Long-acting antipsychotics in the treatment of schizophrenia: opportunities and challenges. Expert Opinion on Pharmacotherapy 24:4, pages 473-493.
Read now
Read now
Georgios Schoretsanitis, Edoardo Spina, Christoph Hiemke & Jose de Leon. (2017) A systematic review and combined analysis of therapeutic drug monitoring studies for long-acting risperidone. Expert Review of Clinical Pharmacology 10:9, pages 965-981.
Read now
Read now
Articles from other publishers (8)
Lorenzo Cellini, Domenico De Donatis, Laura Mercolini, Fabio Panariello, Diana De Ronchi, Alessandro Serretti, Andreas Conca, Davide Gaspari, Giancarlo Giupponi, Gerald Zernig & Vincenzo Florio. (2021) Switch to 3-Month Long-Acting Injectable Paliperidone May Decrease Plasma Levels. Journal of Clinical Psychopharmacology 41:6, pages 694-696.
Crossref
Crossref
Francisco José Toja-Camba, Nerea Gesto-Antelo, Olalla Maroñas, Eduardo Echarri Arrieta, Irene Zarra-Ferro, Miguel González-Barcia, Enrique Bandín-Vilar, Victor Mangas Sanjuan, Fernando Facal, Manuel Arrojo Romero, Angel Carracedo, Cristina Mondelo-García & Anxo Fernández-Ferreiro. (2021) Review of Pharmacokinetics and Pharmacogenetics in Atypical Long-Acting Injectable Antipsychotics. Pharmaceutics 13:7, pages 935.
Crossref
Crossref
Georgios Schoretsanitis, Jose de Leon, Ekkehard Haen, Benedikt Stegmann, Christoph Hiemke, Gerhard Gründer & Michael Paulzen. (2018) Pharmacokinetics of risperidone in different application forms – Comparing long-acting injectable and oral formulations. European Neuropsychopharmacology 28:1, pages 130-137.
Crossref
Crossref
Sarah M. Leatherman, Matthew H. Liang, John H. Krystal, Robert A. Lew, Danielle Valley, Soe Soe Thwin & Robert A. Rosenheck. (2014) Differences in Treatment Effect Among Clinical Subgroups in a Randomized Clinical Trial of Long-Acting Injectable Risperidone and Oral Antipsychotics in Unstable Chronic Schizophrenia. Journal of Nervous & Mental Disease 202:1, pages 13-17.
Crossref
Crossref
Robert A. Rosenheck, John H. Krystal, Robert Lew, Paul G. Barnett, Louis Fiore, Danielle Valley, Soe Soe Thwin, Julia E. Vertrees & Matthew H. Liang. (2011) Long-Acting Risperidone and Oral Antipsychotics in Unstable Schizophrenia. New England Journal of Medicine 364:9, pages 842-851.
Crossref
Crossref
Rosa CatalánRafael Penadés. (2011) Risperidone Long-Acting Injection: Safety and Efficacy in Elderly Patients with Schizophrenia. Journal of Central Nervous System Disease 3, pages JCNSD.S4125.
Crossref
Crossref
W. Wolfgang Fleischhacker. (2018) Second-generation antipsychotic long-acting injections: Systematic review. British Journal of Psychiatry 195:S52, pages s29-s36.
Crossref
Crossref
R. Nesvag, M. Hendset, H. Refsum & L. Tanum. (2006) Serum concentrations of risperidone and 9-OH risperidone following intramuscular injection of long-acting risperidone compared with oral risperidone medication. Acta Psychiatrica Scandinavica 114:1, pages 21-26.
Crossref
Crossref